Our recent study demonstrated that HDAC4 protein specifically increases in mesenteric artery from spontaneous hypertensive rats (SHR) compared with Wistar Kyoto rats (WKY). Vascular inflammation is important for pathogenesis of hypertension. We examined whether HDAC4 affects vascular inflammatory responses and promotes hypertension. In vivo, blood pressure, reactive oxygen species (ROS) production, and VCAM-1 expression in isolated mesenteric artery were elevated in young SHR (7 wk old) compared with age-matched WKY, which were prevented by long-term treatment of SHR with an HDACs inhibitor, trichostatin A (TSA; 500 g·kg Ϫ1 ·day Ϫ1 for 3 wk). In isolated mesenteric artery, the increased angiotensin II-induced contraction in SHR was reversed by TSA. The endothelium-dependent relaxation induced by ACh in SHR was augmented by TSA. In cultured rat mesenteric arterial smooth muscle cells (SMCs), expression of HDAC4 mRNA and protein was increased by TNF-␣ (10 ng/ml). TSA (10 M, pretreatment for 30 min) inhibited VCAM-1 expression and NF-B phosphorylation induced by TNF (10 ng/ml, 24 h or 20 min) in SMCs. HDAC4 small interfering RNA inhibited TNF-induced monocyte adhesion, VCAM-1 expression, transcriptional activity of NF-B, and ROS production in SMCs. The present results demonstrated that proinflammatory effects of HDACs may mediate the further development of hypertension in SHR. It is also suggested in cultured vascular SMCs that TNF-induced HDAC4 mediates vascular inflammation likely via VCAM-1 induction through ROS-dependent NF-B activation. oxygen radicals; smooth muscle; contractile function CAM IS ASSOCIATED WITH A VARIETY of cell functions including inflammation, apoptosis, and muscular contraction. Recent evidence indicates that CaM-related proteins are responsible for cardiovascular diseases. In the previous study, we compared expression levels of six CaM-related proteins with almost unknown functions in vasculature [CaMKII␦, eukaryotic elongation factor 2 kinase (eEF2K; also known as CaMKIII), histone deacetylase (HDAC)4, HDAC5, death associated protein kinase (DAPK)3, and CaM serine kinase (CASK)] in aorta and mesenteric artery from spontaneous hypertensive rats (SHR) and Wistar Kyoto rats (WKY) (48). As a result, we for the first time demonstrated that expressions of eEF2K, HDAC4, and DAPK3 protein increased in SHR compared with WKY. However, it remained to be clarified how each CaM-related protein might affect vascular pathophysiology and control the development of hypertension.
SHR compared with WKY. However, it remained to be clarified how each CaM-related protein might affect vascular pathophysiology and control the development of hypertension.
HDACs have been considered as transcriptional corepressors that catalyze histone deacetylation in diverse physiological systems (33, 42) . Up to now, HDACs have been classified into four groups termed class I HDACs (HDAC1, 2, 3, and 8), class II HDACs (HDAC4, 5, 6, 7, 9, and 10), class III HDACs, and class IV HDAC (HDAC11). The class II HDACs are further divided into the class IIa (HDAC4, 5, 7, 9) and the class IIb (HDAC6 and 10) (26) . A recent study clarified that the class I and IIa HDACs play critical roles in mediating cardiac hypertrophy. For example, HDAC2 was activated by hypertrophic stresses in association with the induction of heat shock protein 70 (17) , mice lacking HDAC5 and/or HDAC9 exhibited exacerbated cardiac hypertrophy in response to stress induced by aortic stenosis (26, 27) , an inhibitor of class I HDACs valproic acid attenuated cardiac hypertrophy in SHR (5) . On the other hand, it was reported that HDAC4 is predominantly associated with muscle and chondrocyte development (28, 50) . In addition, HDAC4 is highly abundant in the brain and promotes neuronal apoptosis (3, 15) . Recently, it was suggested that HDAC4 may regulate cardiovascular diseases. For example, in cultured cardiomyocytes, HDAC4 was regulated by hypertrophic agonists (1) and activation of HDAC4 promoted ANG II-induced vascular smooth muscle hypertrophy (21) . These reports raise the possibility that the class I and IIa HDACs including HDAC4 will become pharmaceutical targets against cardiovascular diseases including hypertension.
Vascular inflammation is known to be important for the pathogenesis of hypertension. In addition, a critical role for inflammation induced by reactive oxygen species (ROS) has been suggested in hypertension (12, 36) . It was shown in human endothelial cells that HDAC3 knockdown by small interfering RNA (siRNA) inhibited monocyte adhesion via the inhibition of VCAM-1 expression (16) . Furthermore, several studies showed that HDACs inhibitor improved cardiac hypertrophy via the inhibition of ROS produced by proinflammatory cytokines (5, 6) . However, it remains to be clarified how HDAC4 controls hypertensive vascular diseases via inflammation. We therefore examined whether HDAC4 affects vascular smooth muscle inflammatory responses and contributes to the further development of hypertension. Here, we for the first time demonstrate that HDAC4 promotes ROS-dependent vascular inflammation and may mediate the further development of hypertension in SHR.
METHODS

Materials.
Reagent sources were as follows: TNF-␣ (Roche Applied Science, Mannheim, Germany); IL-1␤ (PeptroTech, Rocky Hill, NJ); H 2O2 (Kanto Chemical, Tokyo, Japan); ANG II, endothelin (ET)-1, and noradrenaline (NA) (Sigma, St. Louis, MO); ACh (Daiichi Pharmaceutical, Tokyo); and trichostatin A (TSA) (Cayman Chemical, Ann Arbor, MI; Tokyo Chemical Industry, Tokyo, Japan). Antibody sources were as follows: phospho-NF-B p65 (Ser536) (Cell Signaling, Beverly, MA); total NF-B p65 and VCAM-1 (Santa Cruz Biotech, Santa Cruz, CA); total-actin (Sigma Aldrich, St. Louis, MO), ␣-actin (DAKO, Glostrup, Denmark); and HDAC4 and phospho-HDAC4 (Ser622) (Eno Gene, Nanjing, China).
Animal studies. TSA or vehicle (DMSO) was subcutaneously administered to male SHR (4 wk old; Hoshino Laboratory Animals, Ibaragi, Japan) and age-matched male WKY at a dose of 500 g·kg Ϫ1 ·day Ϫ1 (9, 14, 51) for 3 wk. Animal care and treatment were conducted in conformity with institutional guidelines of The Kitasato University and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. This study was approved by the Kitasato University Animal Care and Use Committee.
Blood pressure measurement. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial blood pressure (MBP) of SHR and WKY were measured using a tail-cuff system (Softron, Tokyo, Japan) in the conscious conditions (48) .
Tissue preparation. SHR (0.17-0.19 kg: 7 wk old) and agematched WKY (0.17-0.20 kg) were anesthetized with urethane (1.5 g/kg ip) and euthanized by exsanguination. The superior mesenteric arteries were isolated as described previously (48) . After the fat and connective tissues were removed, the arterial samples were used for the extraction of protein, the measurement of isometric tension, and the histological analysis using frozen sections.
Measurement of intracellular ROS in vascular tissues. Isolated mesenteric artery was embedded in optimal cutting temperature compound (Sakura Finetechnical, Tokyo, Japan) and quickly frozen in liquid nitrogen. Thin frozen sections (10 m) were then made using a cryostat (Leica, Solms, Germany). The frozen sections were loaded with 2=,7=-dichlorodihydrofluorescein diacetate (H2DCFDA; Invitrogen; 5 M) for 30 min. Fluorescence images were obtained using a fluorescence microscope (BX-51; Olympus, Tokyo, Japan) equipped with cooled charge-coupled device camera (MicroPublisher 5.0 RTV, Roper Japan, Tokyo, Japan). The ImageJ software was used for the quantitative analysis of the H2DCFDA images.
Measurement of smooth muscle contraction. The contractility of isolated, endothelium-intact mesenteric artery was measured as described previously (31) . The arterial rings were placed in normal physiological salt solution, which contained (in mM) 139.9 NaCl, 5.4 KCl, 1.5 CaCl2, 1.0 MgCl2, 23.8 NaHCO3, and 5.5 glucose. EDTA (1 M) was also added to remove the contaminating heavy metal ions, which catalyze oxidation of organic chemicals. The high K ϩ (72.4 mM) solution was prepared by replacing NaCl with equimolar KCl. These solutions were saturated with a 95% O 2-5% CO2 mixture at 37°C and pH 7.4. Smooth muscle contractility was recorded isometrically with a force-displacement transducer (Nihon Kohden, Tokyo, Japan). Each muscle ring was attached to a holder under a resting tension of 0.5 g. After equilibration for 30 min in a 3-ml organ bath, each ring was repeatedly exposed to high K ϩ solution until the responses became stable (60 -90 min). Concentration-response curves to ANG II (0.1-30 nM) were obtained by the cumulative application. It was observed that 10 nM ANG II induced the maximal contraction followed by the decrease in contraction by the higher concentration (30 nM) of ANG II perhaps via desensitization. The 72.4 mM KCl-induced maximal contractions were used for normalization, and they were not statistically different in all groups (WKY, 0.9 Ϯ 0.2 g, n ϭ 4; SHR, 0.6 Ϯ 0.3 g, n ϭ 4; SHR ϩ TSA500, 0.5 Ϯ 0.2 g, n ϭ 6; WKY ϩ TSA500, 0.8 Ϯ 0.5 g, n ϭ 5). ACh (1 nM-300 M) was cumulatively applied to the arteries precontracted to the similar level with submaximal concentrations of NA (100 nM-1 M). The NA (100 nM-1 M)-induced contractions used for the precontractions were not statistically different in all groups (WKY, 0.6 Ϯ 0.2 g, n ϭ 7; SHR, 0.5 Ϯ 0.2 g, n ϭ 8; SHR ϩ TSA500, 0.4 Ϯ 0.1 g, n ϭ 6; WKY ϩ TSA500, 0.8 Ϯ 0.5 g, n ϭ 5).
Culture of vascular smooth muscle cells. Smooth muscle cells (SMCs) isolated solely from superior mesenteric artery of male Wistar Fig. 1 . Effects of long-term trichostatin A (TSA) treatment on blood pressure of spontaneous hypertensive rats (SHR). TSA was administered to SHR (4 wk old) or age-matched Wistar Kyoto rats (WKY) subcutaneously at a dose of 500 g·kg Ϫ1 ·day Ϫ1 for 3 wk. Systolic (A; n ϭ 4 -6), mean (B; n ϭ 4 -6), and diastolic (C; n ϭ 4 -6) blood pressure of SHR or WKY were measured using a tail-cuff system at weekly intervals. Results were expressed as means Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01 vs. WKY; #P Ͻ 0.05, ##P Ͻ 0.01 vs. SHR. rats (7 to 9 wk old) were cultured in DMEM supplemented with 10% FBS (Invitrogen, Carlsbad, CA). Passage 4 to 20 SMCs at 80% to 90% confluence were growth arrested by incubating in DMEM containing 0.5% FBS for 6 -16 h before stimulation.
RT-PCR. Total RNA was extracted from SMCs by using QuickGene SP kit (Fuji Film, Tokyo, Japan) according to the instructions of the manufacturer. The first strand cDNA was synthesized using random hexamers and Superscript II RT at 65°C for 5 min, 25°C for 2 min, 25°C for 10 min, 42°C for 50 min, and 70°C for 15 min. PCR amplification was performed using HotStarTaq Master Mix kit (Qiagen). We used the following oligonucleotide primers pairs for HDAC4, sense 5=-GGGGAGCAGCATCATGGTTC-3= and antisense 5=-GCTTCATCTTCACCTCTGTG-3=; for GAPDH, sense 5=-GCT-GATGCCCCCATGTTTG-3= and antisense 5=-GGGTGGTGGAC-CTCATGGC-3=. After initial activation at 95°C for 15 min, 35 cycles of amplifications at 94°C for 0.5 min, 47°C for 0.5 min, and 72°C for 1 min followed by final extension at 72°C for 10 min were done with a thermal cycler (PC707; ASTEC, Fukuoka, Japan). The expected size of HDAC4 and GAPDH is 760 and 611 bp, respectively. PCR products were electrophoresed on 2% agarose gel containing 0.1% ethidium bromide. Detectable fluorescent bands were visualized by a UV transilluminator and analyzed using CS Analyzer 3.0 software (ATTO, Tokyo, Japan).
Western blotting. Western blotting was performed as described previously (48) . Protein lysates were obtained by homogenizing SMCs or tissue samples with triton-based lysis buffer containing 1% Triton X-100, 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerol phosphate, 1 mM NA 3VO4, 1 g/ml leupeptin, and 0.1% protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). Protein concentration was determined using the bicinchoninic acid method (Pierce, Rockford, IL). Equal amount of proteins (10 -15 g) were separated by SDS-PAGE (7.5%) and transferred to a nitrocellulose membrane (Pall, Ann Arbor, MI). After being blocked with 3% BSA (for phosphorylationspecific antibodies) or 0.5% skim milk (for others), membranes were incubated with primary antibodies at 4°C overnight and then visualized using horseradish peroxidase-conjugated secondary antibodies (1:10,000 dilution, 1 h) and the EZ-ECL system (Biological industries, Kibbutz Beit Hesmek, Israel). Equal loading of protein was confirmed by measuring expression of total protein or actin. The results were analyzed using CS Analyzer 3.0 software.
siRNA transfections. One day after SMCs were subcultured, they (30 -40% confluent) were transfected for 24 h with siRNA against HDAC4 (HDAC4 siRNA, GCAGAUCUGUGUUUUGAAA; Nippon EGT, Toyama, Japan) or nonsilencing control siRNA (control siRNA; Qiagen, Valencia, CA) using lipofectamine 2000 (Invitrogen) dissolved in Optimem (Invitrogen) at a final concentration of 40 nmol/l. SMCs were then serum-starved by incubating in DMEM containing 0.5% FBS for 24 h before stimulation.
Cell adhesion assays. U937 (monocytes) cells were obtained from the RIKEN Cell Bank (Tsukuba, Japan) and cultured in RPMI-1640 medium supplemented with 5% FBS. After SMCs transfected with HDAC4 siRNA or control siRNA (40 nM, 24 h) in a 6-well culture plate were stimulated with TNF-␣ (10 ng/ml) for 24 h, they were washed with Tris-buffered saline. U937 cells (ϳ8.5 ϫ 10 5 cells/well) were then coincubated for 1 h with SMCs at 10 rpm at 37°C. Nonattached cell was removed by the washings, the cells were then fixed with 4% paraformaldehyde at 37°C for 10 min. The number of attached U937 cells was randomly counted in three areas per well at ϫ200 fields and averaged.
NF-B transcriptional activity assay. One day after SMCs were subcultured, they (30 -40% confluent) were transfected for 24 h with a mixture (500 ng/ml) of inducible NF-B-responsive firefly luciferase construct and constitutively expressing renilla luciferase con- Fig. 2 . Effects of long-term TSA treatment to SHR on expression of VCAM-1 (A) and reactive oxygen species (ROS) production (B) in an isolated mesenteric artery. After TSA was administered to SHR (4 wk old) subcutaneously at a dose of 500 g·kg Ϫ1 ·day Ϫ1 for 3 wk, superior mesenteric artery was harvested. A: expression of VCAM-1 (n ϭ 4) was determined by Western blotting and shown as fold increase relative to control. Equal protein loading was confirmed using total actin antibody. B: superior mesenteric arteries were embedded in optimal cutting temperature compound, and the thin frozen section (10 m) was made using a cryostat. They were loaded with 2=,7=-dichlorodihydrofluorescein diacetate (H2DCFDA; 5 mol/l) for 30 min, and the fluorescence images were obtained using a fluorescence microscope. Fluorescent intensity was measured using ImageJ software and shown as fold increase relative to control (n ϭ 3 to 4). Scale bar, 50 m. *P Ͻ 0.05, **P Ͻ 0.01 vs. WKY; #P Ͻ 0.05, ##P Ͻ 0.01 vs. SHR. struct as an internal control (40:1) (SA Biosciences, Frederick, MD) using lipofectamine 2000. SMCs were then serum starved by incubating in DMEM containing 0.5% FBS for 24 h before stimulation. After TNF stimulation for 3 h, SMCs were harvested with a passive lysis buffer (Promega, Madison, WI). The NF-B luciferase activity was measured by using the Dual-Glo Luciferase Assay System (Promega) in a chemiluminescence plate reader (Berthold Technologies, Tokyo, Japan).
Measurement of intracellular ROS production in SMCs. After treatment for 20 min with TNF-␣ in the presence of HDAC4 siRNA or control siRNA, SMCs were loaded with H2DCFDA (10 M) for 30 min. Fluorescence images were obtained and analyzed as described above.
Statistical analysis. Data are shown as means Ϯ SE. Statistical evaluations were performed using one-way ANOVA followed by Bonferroni test. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
Effects of long-term TSA treatment on blood pressure of SHR.
We first examined the effects of an inhibition of HDACs on the further development of hypertension in young SHR (4 wk old). The SBP, MBP, and DBP were significantly higher in SHR than WKY (Fig. 1A , SBP at 7 wk old, SHR 153.1 Ϯ 0.4, n ϭ 4 vs. WKY 110.8 Ϯ 4.9 mmHg, n ϭ 6, P Ͻ 0.01; Fig. 1B , MBP at 7 wk old, SHR 124 Ϯ 1.4, n ϭ 4 vs. WKY 90.1 Ϯ 3.9 mmHg, n ϭ 6, P Ͻ 0.01; Fig. 1C , DBP at 7 wk old, SHR 109.7 Ϯ 1.9, n ϭ 4 vs. WKY 79.9 Ϯ 3.5 mmHg, n ϭ 6, P Ͻ 0.01). TSA (500 g·kg Ϫ1 ·day Ϫ1 ) treatment significantly decreased the blood pressure (BP) in SHR (Fig. 1A , SBP at 7 wk old, SHR ϩ TSA500 139.7 Ϯ 2.0 mmHg, n ϭ 4, P Ͻ 0.01 vs. SHR; Fig. 1B , MBP at 7 wk old, SHR ϩ TSA500 115.4 Ϯ 3.0 mmHg, n ϭ 4, P Ͻ 0.05 vs. SHR; Fig. 1C , DBP at 7 wk old, SHR ϩ TSA500 103.4 Ϯ 3.9 mmHg, n ϭ 4). Nevertheless, the BP in SHR with TSA treatment is significantly higher than that in WKY. Long-term treatment of WKY with TSA (500 g·kg Ϫ1 ·day
Ϫ1
) had no effects on the BP (Fig. 1 , A-C, n ϭ 5).
Effects of long-term TSA treatment on VCAM-1 expression and ROS production of isolated mesenteric artery in SHR.
Vascular inflammation is important for development of hypertension. To examine whether HDACs mediate vascular inflammation in vivo, we examined the effects of long-term TSA treatment on expression of VCAM-1 in isolated mesenteric artery from SHR. The expression of VCAM-1 in SHR (7 wk old) was significantly increased compared with Fig. 3 . Effects of long-term TSA treatment on ANG II-induced contraction of isolated mesenteric artery (A). After TSA was administered to SHR (4 wk old) or WKY (4 wk old) subcutaneously at a dose of 500 g·kg Ϫ1 ·day Ϫ1 for 3 wk, superior mesenteric artery was harvested. Concentration-contraction relationships to ANG II (WKY, OE, n ϭ 4; SHR, , n ϭ 4; SHR ϩ TSA500, ' , n ϭ 6; and WKY ϩ TSA500, , n ϭ 5) were shown. ANG II (0.1-30 nM) was cumulatively applied. Results were expressed as means Ϯ SE. One hundred percent represents 72 mM KCl-induced maximal contraction. B: effects of TSA treatment on ACh-induced endothelium-dependent relaxation of isolated mesenteric artery. Concentration-contraction relationships to ACh (WKY, OE, n ϭ 7; SHR, , n ϭ 8; SHR ϩ TSA500, ' , n ϭ 6; and WKY ϩ TSA500, , n ϭ 5) were shown. ACh (1 nM-10 M) was cumulatively added after the precontraction induced by noradrenaline (100 nM-1 M) had reached a steady state. One hundred percent represents noradrenaline-induced precontraction. Results were expressed as means Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01 vs. WKY; #P Ͻ 0.05, ##P Ͻ 0.01 vs. SHR. α α α Fig. 4 . Expression levels of histone deacetylase (HDAC)4 mRNA in cultured vascular smooth muscle cells (SMCs). After rat mesenteric arterial SMCs were treated with 10 ng/ml TNF-␣, 4 ng/ml IL-1␤, 300 mol/l H2O2, 0.1 M ANG II, and 0.1 M endothelin (ET)-1 for 24 h, total RNA was harvested. Expression of HDAC4 mRNA was determined by RT-PCR analysis using the gene specific primers to rat HDAC4 (expected size, 760 bp). Equal loading of template cDNA was confirmed by ensuring the GAPDH (611 bp) expression (n ϭ 6 to 7). Expression of HDAC4 was shown as fold increase relative to control. **P Ͻ 0.01 vs. cont. Fig. 2A) . TSA (500 g·kg Ϫ1 ·day Ϫ1 , 3 wk) treatment significantly prevented the increased expression of VCAM-1 in SHR (SHR; 1.5 Ϯ 0.1-fold relative to WKY, n ϭ 4 vs. SHR ϩ TSA500; 0.8 Ϯ 0.1-fold, n ϭ 4, P Ͻ 0.05). Long-term TSA (500 g·kg Ϫ1 ·day Ϫ1 , 3 wk) treatment had no effect on the expression of VCAM-1 in WKY (n ϭ 4, data not shown). We further examined whether long-term TSA treatment attenuates ROS production in mesenteric artery from SHR. In mesenteric artery from SHR (7 wk old), fluorescence intensity of ROSsensitive H 2 DCFDA significantly increased compared with that from WKY (Fig. 2B) . Long-term TSA (500 g·kg Ϫ1 ·day Ϫ1 , 3 wk) treatment significantly inhibited the ROS production in mesenteric artery from SHR (SHR; 2.1 Ϯ 0.1-fold relative to WKY, n ϭ 4 vs. SHR ϩ TSA500; 1.1 Ϯ 0.1-fold, n ϭ 3, P Ͻ 0.01).
WKY (
Effects of long-term TSA treatment on ANG II-induced contraction of isolated mesenteric artery in SHR.
To further explore mechanisms of the TSA-mediated decreases in BP of SHR, we examined whether long-term TSA treatment affects hypercontractility of mesenteric artery from SHR. There are reports showing that NA and ET-1-induced contraction did not change in thoracic aorta and mesenteric vascular bed between SHR and WKY (30, 46) . On the other hand, it was shown in mesenteric artery of young SHR (5 to 6 wk old) that ANG II-induced contraction was augmented compared with WKY (13). Thus we especially focused on ANG II-induced contraction in this study. In mesenteric artery from WKY (7 wk old), ANG II (0.1-30 nM) induced a slight contraction (Fig. 3A) . In mesenteric artery from SHR, the ANG II-induced contraction was significantly augmented (Fig. 3A) . Long-term TSA (500 g·kg Ϫ1 ·day Ϫ1 , 3 wk) treatment reversed the augmented ANG II-induced contraction in SHR (Fig. 3A , SHR ϩ TSA500 19.5 Ϯ 7.5%, n ϭ 6 vs. SHR 60.4 Ϯ 10.9% relative to 72.4 mM KCl-induced maximal contraction, n ϭ 4, P Ͻ 0.05). Long-term TSA (500 g·kg Ϫ1 ·day Ϫ1 , 3 wk) treatment had no effect on the ANG II-induced contraction in WKY (Fig. 3A, n ϭ 5) . The PD 2 (Ϫlog EC 50 ) values for the ANG II-induced contraction were similar in all groups (WKY 8.4, n ϭ 4; SHR 8.5, n ϭ 4; SHR ϩ TSA500 8.5, n ϭ 6; WKY ϩ TSA500 8.4, n ϭ 5).
Effects of long-term TSA treatment on ACh-induced relaxation of isolated mesenteric artery in SHR. We next examined the effects of long-term TSA treatment on ACh-induced endothelium-dependent relaxation of mesenteric artery from SHR. In mesenteric artery from WKY (7 wk old), ACh (0.1 nM-10 M) induced relaxation of the NA-induced precontraction in a concentration-dependent manner (Fig. 3B) . In mesenteric artery from SHR, the ACh-induced relaxation was not changed from WKY (Fig. 3B) . Long-term TSA (500 g·kg Ϫ1 ·day
Ϫ1
, 3 wk) treatment significantly enhanced the ACh-induced relaxation in SHR (Fig. 3B , at ACh 30 nM; SHR ϩ TSA500 75.6 Ϯ 4.4%, n ϭ 6 vs. SHR 40.4 Ϯ 8.7%, n ϭ 8, P Ͻ 0.01). Long-term TSA (500 g·kg Ϫ1 ·day Ϫ1 , 3 wk) treatment had no effect on the ACh-induced relaxation in WKY (Fig. 3B, n ϭ 5 ). The PD 2 values for the ACh-induced relaxation were as follows: WKY 7.4, n ϭ 7; SHR 7.4, n ϭ 8; SHR ϩ TSA500 8.0, n ϭ 6; WKY ϩ TSA500 7.2, n ϭ 5.
Induction of HDAC4 by inflammatory stimulations in cultured vascular SMCs. Our data in vivo suggest that HDACs may mediate the development of hypertension likely via in- Fig. 5 . Expression levels of HDAC4 protein in SMCs. After SMCs were treated with 10 ng/ml TNF-␣ for 20 min-12 h, total cell lysates were harvested. Expression of HDAC4 protein was determined by Western blotting and shown as fold increase relative to control (n ϭ 3-5). Equal protein loading was confirmed using ␣-actin antibody. **P Ͻ 0.01 vs. cont. Fig. 6 . Effects of TNF-␣ stimulation on HDAC4 activity in SMCs. After SMCs were treated with 10 ng/ml TNF for 20 min and 1, 3, and 6 h, total cell lysates were harvested. Phosphorylation (at Ser632) or total expression of HDAC4 was determined by Western blotting (n ϭ 3). Equal protein loading was confirmed using ␣-actin antibody. Phosphorylation level of HDAC4 normalized to total HDAC4 expression level was shown as fold increase relative to control. **P Ͻ 0.01 vs. cont. flammation. We next specifically focused on the involvement of HDAC4 in vascular inflammation using the cultured vascular SMCs. We then first examined whether expression level of HDAC4 mRNA is modulated by inflammatory stimulations (24 h), including TNF-␣(10 ng/ml), IL-1␤(4 ng/ml), H 2 O 2 (300 M), ANG II (0.1 M), and ET-1 (0.1 M). Among them, TNF-increased HDAC4 mRNA was the most significant (TNF; 1.9 Ϯ 0.3-fold relative to control, n ϭ 6 to 7, P Ͻ 0.01; Fig. 4) . ET-1 also moderately increased the HDAC4 mRNA (ET-1; 1.3 Ϯ 0.1-fold relative to control, n ϭ 6 to 7, P Ͻ 0.01; Fig.  4 ). We next examined whether TNF increases protein expression of HDAC4. TNF increased HDAC4 protein in a timedependent manner (TNF for 3 h; 1.7 Ϯ 0.1-fold relative to control, n ϭ 3-5, P Ͻ 0.01; Fig. 5 ). At 12 h, TNF-induced increase in HDAC4 protein began to decline. TNF-induced activation of HDAC4 was next measured. HDAC4 is activated by phosphorylation at serine 632 (21) . Phosphorylation of HDAC4 at serine 632 was significantly increased by TNF (10 ng/ml) at 1 h (1.9 Ϯ 0.1-fold relative to control, n ϭ 3, P Ͻ 0.01; Fig. 6 ).
Effects of TSA on TNF-␣-induced expression of VCAM-1.
To explore whether HDAC4 mediates TNF-induced inflammatory responses in vascular SMCs, effects of TSA on TNF-␣-induced expression of VCAM-1 were first examined. We confirmed that TSA (10 M, pretreatment for 30 min) effectively inhibited TNF (10 ng/ml, 1 h)-induced HDAC4 phosphorylation (at Ser 632; TNF; 1.6 Ϯ 0.1-fold relative to control, n ϭ 4 vs. TNF ϩ TSA; 1.1 Ϯ 0.1-fold relative to control, n ϭ 4, P Ͻ 0.05; Fig. 7A ). TNF (10 ng/ml, 24 h)-induced VCAM-1 was significantly inhibited by TSA (10 M, 30 min) (TNF; 5.2 Ϯ 0.5-fold relative to control, n ϭ 4 vs. TNF ϩ TSA; 2.6 Ϯ 0.4-fold relative to control, n ϭ 4, P Ͻ 0.01; Fig. 7B) .
Effects of TSA on TNF-␣-induced activation of NF-B signals.
To determine mechanisms of TSA to inhibit TNFinduced VCAM-1 expression, TNF-induced activation of NF-B was next examined. TNF (10 ng/ml, 20 min)-induced phosphorylation of NF-B p65 (Ser536) was significantly inhibited by TSA (10 M, 30 min) (TNF; 1.5 Ϯ 0.1-fold relative to control, n ϭ 4 vs. TNF ϩ TSA; 1.3 Ϯ 0.1-fold relative to control, n ϭ 4, P Ͻ 0.05; Fig. 7C) .
Effect of HDAC4 knockdown on TNF-␣-induced VCAM-1 expression.
To further clarify the roles of HDAC4 on inflammatory responses in SMCs, HDAC4 gene was specifically silenced by HDAC4 siRNA transfection (40 nM, 24 h) into SMCs. We confirmed that HDAC4 protein was significantly decreased by an HDAC4 siRNA treatment (0.6 Ϯ 0.1-fold relative to control siRNA, n ϭ 4, P Ͻ 0.01; Fig. 8A ). TNF (10 ng/ml, 24 h)-induced VCAM-1 expression was significantly inhibited by an HDAC4 siRNA treatment (control siRNA ϩ TNF; 9.4 Ϯ 0.5-fold relative to control siRNA without TNF stimulation, n ϭ 6 vs. HDAC4 siRNA ϩ TNF; 5.3 Ϯ 0.6-fold, n ϭ 7, P Ͻ 0.01; Fig. 8B ). HDAC4 siRNA had no effect on basal VCAM-1 expression (n ϭ 5; Fig. 8B) .
Effect of HDAC4 knockdown on TNF-␣-induced monocyte adhesion to SMCs.
To test whether HDAC4 knockdown could inhibit monocyte adhesion to SMCs, SMCs were transfected with HDAC4 siRNA (40 nM, 24 h) before TNF stimulation (10 ng/ml, 24 h) and then cocultured with monocytes (U937 cells) for 1 h. The HDAC4 knockdown significantly decreased the number of monocyte adhesion to SMCs (control siRNA ϩ Fig. 7 . Effects of TSA on TNF-␣-induced HDAC4 activation (A). After SMCs were treated with 10 ng/ml TNF for 1 h in the absence or presence of TSA (10 M, pretreatment for 30 min), total cell lysates were harvested. Phosphorylation or total expression of HDAC4 (Ser632) was determined by Western blotting (n ϭ 4). Equal protein loading was confirmed using ␣-actin antibody. Phosphorylation level of HDAC4 normalized to total level of HDAC4 was shown as fold increase relative to control. B: effects of TSA on TNF-␣-induced VCAM-1 expression in SMCs. After SMCs were treated with 10 ng/ml TNF for 24 h in the absence or presence of TSA (10 M, pretreatment for 30 min), total cell lysates were harvested. Expression of VCAM-1 was determined by Western blotting and shown as fold increase relative to control (n ϭ 4). Equal protein loading was confirmed using ␣-actin antibody. C: effects of TSA on TNF-induced activation of NF-B. SMCs were treated with 10 ng/ml TNF for 20 min in the absence or presence of TSA (10 M, pretreatment for 30 min). Phosphorylation of NF-B p65 (Ser536; n ϭ 4) was determined by Western blotting and shown as fold increase relative to control. Equal protein loading was confirmed using total NF-B p65 antibody. **P Ͻ 0.01 vs. cont; #P Ͻ 0.05, ##P Ͻ 0.01 vs. TNF. TNF; 7.0 Ϯ 1.7-fold relative to control siRNA without TNF stimulation, n ϭ 7 vs. HDAC4 siRNA ϩ TNF; 2.4 Ϯ 0.6-fold, n ϭ 7, P Ͻ 0.05; Fig. 8C ). HDAC4 siRNA had no effect on basal monocyte adhesion to SMCs (n ϭ 3; Fig. 8C) .
Effects of HDAC4 knockdown on TNF-␣-induced activation of NF-B pathways.
To explore the upstream mechanisms of inhibition of VCAM-1 induction by HDAC4 siRNA, effects on TNF-induced activation of NF-B were next examined. TNF (10 ng/ml, 20 min)-induced phosphorylation of NF-B p65 (Ser536) was significantly inhibited by HDAC4 siRNA (control siRNA ϩ TNF; 2.9 Ϯ 0.5-fold relative to control siRNA without TNF stimulation, n ϭ 6, vs. HDAC4 siRNA ϩ TNF; 1.3 Ϯ 0.1-fold, n ϭ 8, P Ͻ 0.01; Fig. 9A ). HDAC4 siRNA had no effect on basal NF-B phosphorylation (n ϭ 4; Fig. 9A ). In addition, TNF (10 ng/ml, 3 h)-induced transcriptional activity of NF-B was inhibited by HDAC4 siRNA (control siRNA ϩ TNF; 6.5 Ϯ 0.9-fold relative to control siRNA without TNF stimulation, n ϭ 5, vs. HDAC4 siRNA ϩ TNF; 3.5 Ϯ 0.9-fold, n ϭ 4, P Ͻ 0.05; Fig. 9B ). HDAC4 siRNA had no effect on basal transcriptional activity of NF-B (n ϭ 3; Fig. 9B) .
Effects of HDAC4 knockdown on TNF-␣-induced ROS production.
To further explore the upstream mechanisms, we examined whether HDAC4 knockdown attenuates TNF-induced ROS production in SMCs. TNF (10 ng/ml, 20 min) increased H 2 DCFDA-sensitive fluorescent intensity compared with nonstimulated control (Fig. 9C ). HDAC4 siRNA (40 nM, 24 h) significantly inhibited the TNF-induced ROS production (control siRNA ϩ TNF; 1.6 Ϯ 0.1-fold relative to control siRNA without TNF stimulation, n ϭ 5 vs. HDAC4 siRNA ϩ TNF; 1.1 Ϯ 0.1-fold, P Ͻ 0.01, n ϭ 5; Fig. 9C ). HDAC4 siRNA had no effect on basal ROS production (n ϭ 3; Fig. 9C ).
DISCUSSION
HDACs are repressive transcriptional regulators and involved in various signaling pathways (19, 40) . Although (siRNA; A) . After SMCs were transfected with HDAC4-specific siRNA (HDAC4 siRNA) or nonsilencing control siRNA (control siRNA) (40 nM, 24 h, n ϭ 4), total cell lysates were harvested. Expression of HDAC4 protein was determined by Western blotting and shown as fold increase relative to control siRNA. Equal protein loading was confirmed using ␣-actin. **P Ͻ 0.01 vs. control siRNA. B: effects of HDAC4 knockdown on TNF-␣-induced VCAM-1 expression. After SMCs were transfected with HDAC4 siRNA or control siRNA (40 nM, 24 h, n ϭ 5-7), SMCs were treated with 10 ng/ml TNF for 24 h. Expression of VCAM-1 was shown as fold increase relative to control siRNA without TNF stimulation. Equal protein loading and efficiency of HDAC4 knockdown were confirmed using ␣-actin and total HDAC4 antibody, respectively. C: effects of HDAC4 knockdown on monocytes adhesion to SMCs. After SMCs were transfected with HDAC4 siRNA (40 nM, 24 h, n ϭ 3-7), TNF-␣ (10 ng/ml, 24 h) were treated. After U937 cells were added for 1 h to SMCs, nonattached cells were removed by the washings, and the number of attached U937 cells was randomly counted in 3 areas (ϫ200 fields) and averaged. Scale bar, 50 m. The number of U937 cells attached to SMCs was shown as fold increase relative to control siRNA without TNF stimulation. We rearranged the blots in B, and it was shown by the dividing line. **P Ͻ 0.01 vs. TNF (Ϫ); #P Ͻ 0.05, ##P Ͻ 0.01 vs. cont siRNA ϩ TNF.
HDAC4, a class IIa HDAC, is predominantly associated with muscle and chondrocyte development (28, 50) as well as neuronal death (3), accumulating evidence indicated that HDAC4 may regulate cardiovascular diseases through the promotion of hypertrophy (1, 21) . In the current study, we aimed to clarify whether HDAC4 mediates hypertension mainly through the activation of vascular inflammatory responses. The major findings of the present study are that proinflammatory effects of HDACs may mediate the further development of hypertension in SHR. In addition, we showed in cultured SMCs that TNF-␣ increased expression and activity of HDAC4 and that HDAC4 knockdown inhibited TNF-induced ROS production, activation of NF-B, VCAM-1 expression, and monocyte adhesion. In the previous study, we showed in cultured vascular SMCs that an NF-B inhibitor, pyrrolibine dithiocarbamate, or an antioxidant drug, N-acetyl cysteine inhibited TNF-induced VCAM-1 expression. In addition, N-acetyl cysteine inhibited TNF-induced phosphorylation of NF-B (49). Collectively, our results indicate that TNFinduced HDAC4 mediates vascular inflammation via VCAM-1 induction through ROS-dependent NF-B activation in vascular SMCs, which may be at least in part responsible for the development of hypertension (Fig. 10) .
It is known that chronic hypertension is a major risk factor for cardiovascular diseases such as heart failure. Several reports demonstrated that HDACs are unique and attractive therapeutic targets for heart failure (4, 8) . In the present study, we examined the contributions of HDACs on the development of hypertension using young SHR (4 wk old) with focusing on BP, vascular contraction, inflammatory protein expression, and ROS production. It was reported previously in mesenteric artery from SHR that an increase in ANG II-induced contraction correlated with development of hypertension (47) . In the same report, it was shown that ANG II type 2 (AT) 2 receptor expression level in young SHR (6 wk old) was higher compared with age-matched WKY and adult SHR (21 wk old). In The results were shown as fold increase relative to control siRNA without TNF stimulation. B: effects of HDAC4 knockdown on TNF-␣-induced NF-B transcriptional activity. SMCs were transiently transfected with a mixture of inducible NF-B-responsive firefly luciferase construct and constitutively expressing renilla luciferase construct (40:1; 500 ng/ml, 24 h). After SMCs were treated with 10 ng/ml TNF for 3 h in the absence or presence of HDAC4 siRNA or control siRNA (40 nM, 24 h, n ϭ 3-5), total cell lysates were harvested. Luciferase activity of the lysates was measured using the Dual-Glo Luciferase Assay System. NF-B response element-dependent firefly-luciferase activities were normalized to the luciferase activities generated by the renilla-luciferase control reporter. The results were shown as fold increase control siRNA without TNF stimulation. C: effects of HDAC4 knockdown on TNF-␣-induced ROS production. ROS production in SMCs was determined by a fluorescence staining using H2DCFDA. After SMCs were treated with 10 ng/ml TNF for 20 min in the presence of HDAC4 siRNA or control siRNA (40 nM, 24 h, n ϭ 3-5), SMCs were loaded with H2DCFDA (10 M) for 30 min. Images were obtained using a fluorescence microscope. Scale bar, 50 m. Fluorescent intensity was measured using ImageJ software and shown as fold increase relative to control siRNA without TNF stimulation. We rearranged the blots in A, and it was shown by the dividing line. **P Ͻ 0.01 vs. TNF (Ϫ); #P Ͻ0.05, ##P Ͻ 0.01 vs. cont siRNA ϩ TNF.
addition, a specific AT 2 receptor blocker, PD123319, significantly reduced the increased ANG II-induced contraction in young SHR. These results suggest that ANG II-induced contraction in mesenteric artery of young SHR was regulated by AT 2 receptor. We showed in this study that long-term TSA treatment inhibited the increased ANG II-induced contraction and ROS production in mesenteric artery from young SHR (7 wk old), whereas the results were obtained from the main branch of the superior mesenteric artery. It was reported that AT 2 receptor stimulation interacted with AT 1 receptor stimulation (34) , which activated NADPH oxidase (10, 24) . Furthermore, it was recently demonstrated that a heat shock-induced ROS production augmented ANG II-induced contraction in aorta (18) . Therefore it might be possible that TSA inhibits the increased ANG II-induced contraction presumably via inhibition of ROS production through AT 2 receptor blockade. In the present study, we also showed that the ACh-induced relaxation in mesenteric artery from SHR was not changed from WKY. Several studies reported that ACh-induced relaxation in the isolated artery from adult SHR (12 wk old) was impaired compared with WKY (2, 52) . In contrast, it was reported that the ACh-induced relaxation in the isolated artery from young SHR was not changed from WKY since the vascular endothelial damage of young SHR (4 wk old) is not as serious (11, 39, 46) , supporting our results. Of interest, our results showed that long-term TSA treatment enhanced the ACh-induced relaxation in SHR. It was reported in aorta of SHR that uncoupling of endothelial nitric oxide (NO) synthase leads to ROS production (22) . Therefore, we speculate that TSA inhibited ROS and in turn increased bioactive NO, which led to the enhanced relaxation to ACh. Collectively, it is presumed that long-term TSA treatment prevented an increase in blood pressure of young SHR not only via inhibition of ANG II-induced contraction but also via increment of endothelium-dependent relaxation.
It is known that hypertension is associated with early inflammatory responses such as activation of monocytes and increased adhesion molecules (25) . In this study, we showed that long-term TSA treatment inhibited the increased VCAM-1 expression and ROS production in mesenteric artery from SHR. There are several reports showing that ROS and inflammatory cytokines are produced in the blood or cardiovascular tissues of hypertensive condition, which induce inflammatory molecules such as VCAM-1 and cyclooxygenase 2 and propagate inflammatory vascular diseases (29, 32) . In addition, it was demonstrated that a long-term treatment of antioxidant drugs prevented the development of hypertension via inhibition of inflammatory responses (37, 43) . These reports imply that TSA prevented the development of hypertension likely via inhibition of ROS-mediated early inflammatory responses. In addition, because it was reported in mice vascular smooth muscle that HDAC4 regulates ANG II-induced vascular hypertrophy via activation of myocyte enhancer factor 2, HDACs may also regulate the development of hypertension through vascular hypertrophy in addition to inflammation (21) . However, because vascular hypertrophy is not still so serious in young SHR, we speculate that TSA blunted the further development of hypertension mainly via inhibition of early vascular inflammation rather than hypertrophy. Furthermore, vascular inflammation is also defined by an accumulation of immune cells such as dendritic cells and T cells in the vascular walls. It was reported that the responses of Th1 cells and the regulatory T cells could regulate the vascular inflammation, which may affect the cardiovascular diseases (44) . In addition, it was demonstrated that an HDACs inhibitor increased the production of IL-10-producing regulatory T cells, which prevented inflammatory bowel diseases (45) . Therefore, it might also be possible that TSA treatment can induce regulatory T cells, which produce the anti-inflammatory cytokine IL-10 that decreases NF-B and may play a role in lowering of blood pressure in SHR.
Although we did not compare the expression levels of TNF-␣ in mesenteric artery between SHR and WKY, a previous report showed that mRNA expression of TNF-␣ was higher in the prehypertensive cardiac tissues of SHR compared with age-matched WKY (2 wk old) (41) . In addition, it was also reported that plasma concentration of TNF-␣ in SHR (13 to 17 wk old) was higher than age-matched WKY (7) . It was demonstrated that the increased proinflammatory gene expressions including TNF-␣ and IL-6 correlated with increased blood pressure in SHR (23) . Thus, in the present study, we next examined whether prevention of HDAC4 inhibits TNF-induced inflammatory responses in cultured SMCs. We demonstrated that both the knockdown and the pharmacologic inhibition of HDAC4 prevented TNF-induced activation of NF-B in cultured vascular SMCs. Nevertheless, it remains to be clarified how HDAC4 regulates activation of NF-B in SMCs. It was reported that HDAC4 was exported out of nuclei by ANG II stimulation (21) in SMCs and that HDAC4 was exported to the cytoplasm in response to phenylephrine in cultured cardiomyocytes (1) . On the other hand, in cultured cerebellar granule cells, HDAC4 was translocated into the nuclei in response to low potassium or excitotoxic glutamate, which induced neuronal cell death (3). It was also reported that HDACs deacetylated NF-B, which increased its DNA binding and caused transcriptional activation (38) . In this study, HDAC4 knockdown inhibited TNF-induced phosphorylation and transcriptional activity of NF-B. Thus it is suggested that TNF-activated HDAC4 promotes activation of NF-B not only by releasing the suppression through moving out of nuclei but also by deacetylation.
In the present study, we demonstrated that both the knockdown and the pharmacologic inhibition of HDAC4 prevented TNF-induced expression of VCAM-1 in cultured vascular SMCs. It was reported that induction of VCAM-1 was observed in smooth muscle of human coronary atherosclerotic lesions (35) . It was suggested in the article that VCAM-1 induction increased the adhesion of monocyte to SMCs. Increased adhesion of monocyte to SMCs can stimulate a secretion of inflammatory mediators, which further propagates inflammatory reactions. In the present study, we showed that knockdown of HDAC4 inhibited TNF-induced monocyte adhesion to SMCs. Because it is known that hypertension is associated with inflammation such as activation of monocytes and increased adhesion molecules (25) , it seems likely that TNF-induced HDAC4 in SMCs may mediate the further development of hypertension at least in part through increasing VCAM-1-mediated monocyte adhesion.
In the present study, we showed that knockdown of HDAC4 inhibited TNF-induced ROS generation in SMCs. Nevertheless, it remains to be clarified how HDAC4 regulates TNFinduced ROS production in SMCs. It is well known that HDACs inhibitors activate genes that promote cell cycle arrest and apoptosis in a number of tumor cells (20) . This effect was accompanied by the induction of ROS. For example, it was shown that inhibition of HDAC10 induced release of cytochrome c and activated apoptotic signaling through accumulation of ROS in SNU-620 human gastric cancer cells (20) . In contrast, it was demonstrated that TSA-induced cardioprotection against ischemia and reperfusion injury was eliminated with genetic deletion of gp91 phox expression, a major catalytic subunit of NADPH oxidase (53) . It was further shown that HDACs inhibitor decreased gp91 phox expression in the left ventricle tissues from SHR (5) . With consideration of these results, it is suggested that HDAC4 promotes ROS production via activation of NADPH oxidase in SMCs.
In summary, we for the first time demonstrated that HDAC4 promotes ROS-dependent vascular inflammation and may mediate the further development of hypertension in SHR. Further studies on HDAC4 might contribute to gain mechanistic insights into the pathogenesis of hypertension.
